Jan/Feb/March Volume 23, Issue 1, First Report Managed Care
Videos
03/30/2026
Andy De, CMO
A guest expert explains why generative AI has largely stalled in health care and argues that agentic AI—focused on automating workflows and driving action—offers a more practical path to measurable ROI, improved clinician productivity, and...
A guest expert explains why generative AI has largely stalled in health care and argues that agentic AI—focused on automating workflows and driving action—offers a more practical path to measurable ROI, improved clinician productivity, and...
A guest expert explains why...
03/30/2026
First Report Managed Care
Regulatory Insights
03/30/2026
Adam Colborn, JD
New federal PBM reforms, heightened scrutiny of health care consolidation, and the expansion of direct-to-consumer drug models are poised to reshape the policy landscape, with uncertain implications for patient costs and market dynamics.
New federal PBM reforms, heightened scrutiny of health care consolidation, and the expansion of direct-to-consumer drug models are poised to reshape the policy landscape, with uncertain implications for patient costs and market dynamics.
New federal PBM reforms,...
03/30/2026
First Report Managed Care
MANAGED CARE Q&A
03/26/2026
Abby Reynolds, PharmD
In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.
In this interview, a guest expert explains why emotional readiness—not motivation or access alone—often determines whether patients can successfully initiate and persist on specialty therapies.
In this interview, a guest...
03/26/2026
First Report Managed Care
MANAGED CARE Q&A
03/26/2026
Allison Oakes, PhD
A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.
A guest expert explains why specialty drugs dominating US spending is forcing payers to rethink benefit design, oncology strategy, and biosimilar adoption to control costs and improve value.
A guest expert explains why...
03/26/2026
First Report Managed Care
